Discovery of macrocyclic inhibitors of challenging protein-protein interactions

Solid-phase peptide synthesis in 384-well plates

M. Schuttel; E. Will; G. Sangouard; A. S. L. Zarda; S. Habeshian et al. 

Cyclic Peptides for Drug Development

X. Ji; A. L. Nielsen; C. Heinis 

Methods for high-throughput synthesis and screening of peptide libraries

Development of cyclic peptides that can be administered orally to inhibit disease targets

M. L. Merz; C. Heinis 

De novo development of small cyclic peptides that are orally bioavailable

M. L. Merz; S. Habeshian; B. Li; J-A. G. L. David; A. L. Nielsen et al. 

High-Density Immobilization of TCEP on Silica Beads for Efficient Disulfide Reduction and Thiol Alkylation in Peptides

M. Schuettel; C. Heinis 

Peptide-Hypervalent Iodine Reagent Chimeras: Enabling Peptide Functionalization and Macrocyclization

X-Y. Liu; X. Ji; C. Heinis; J. Waser 

High-affinity peptides developed against calprotectin and their application as synthetic ligands in diagnostic assays

C. Diaz-Perlas; B. Ricken; L. Farrera-Soler; D. Guschin; F. Pojer et al. 

Motifs for making tricycles

C. Heinis 

Development of methods for the synthesis of large combinatorial libraries of macrocyclic compounds

Solid-phase peptide synthesis on disulfide-linker resin followed by reductive release affords pure thiol-functionalized peptides

Z. Bognar; G. K. Mothukuri; A. L. Nielsen; M. L. Merz; P. M. F. Panzar et al. 

Synthesis and direct assay of large macrocycle diversities by combinatorial late-stage modification at picomole scale

S. Habeshian; M. L. Merz; G. Sangouard; G. K. Mothukuri; M. Schüttel et al. 

Cyclative Release Strategy to Obtain Pure Cyclic Peptides Directly from the Solid Phase

S. Habeshian; G. A. Sable; M. Schuettel; M. L. Merz; C. Heinis 

Generating macrocyclic inhibitors of protein-protein interactions

Generation of a 100-billion cyclic peptide phage display library having a high skeletal diversity

V. Carle; X-D. Kong; A. Comberlato; C. Edwards; C. Diaz-Perlas et al. 

Towards the Development of Orally Available Peptide Therapeutics

X-D. Kong; C. Heinis 

Combination of polycarboxybetaine coating and factor XII inhibitor reduces clot formation while preserving normal tissue coagulation during extracorporeal life support

N. Naito; R. Ukita; J. Wilbs; K. Wu; X. Lin et al. 

Cys-Cys and Cys-Lys Stapling of Unprotected Peptides Enabled by Hypervalent Iodine Reagents

J. Ceballos; E. Grinhagena; G. Sangouard; C. Heinis; J. Waser 

Methods for the generation of large combinatorial macrocycle libraries

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

J. Wilbs; X-D. Kong; S. J. Middendorp; R. Prince; A. Cooke et al. 

Macrocycle synthesis strategy based on step-wise “adding and reacting” three components enables screening of large combinatorial libraries

G. K. Mothukuri; S. S. Kale; C. L. Stenbratt; A. Zorzi; J. Vesin et al. 

Novel Molecular Probes for Non-invasive Optical Imaging of Fatty Acid and Triglyceride Uptake in Living Animals

Development of cyclic peptide inhibitors of coagulation factor XIa for safer anticoagulation

Development of Tissue Kallikrein Inhibitors for the Treatment of Netherton Syndrome

Development of cyclic peptide inhibitors of coagulation factor XII and matrix metalloproteinase 2

Bypassing bacterial infection in phage display by sequencing DNA released from phage particles

C. Villequey; X-D. Kong; C. Heinis 

Cyclic peptide therapeutics: past, present and future

A. Zorzi; K. Deyle; C. Heinis 

Phage Selection of Cyclic Peptides for Application in Research and Drug Development

K. Deyle; X-D. Kong; C. Heinis 

Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides

A. Zorzi; S. J. Middendorp; J. Wilbs; K. Deyle; C. Heinis 

Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity

S. J. Middendorp; J. Wilbs; C. Quarroz; S. Calzavarini; A. Angelillo-Scherrer et al. 

Development of an albumin-binding ligand for prolonging the plasma half-life of peptide therapeutics

New methods for developing (bi)cyclic peptides by phage display

Improving the binding affinity of in-vitro-evolved cyclic peptides by inserting atoms into the macrocycle backbone

J. Wilbs; S. J. Middendorp; C. Heinis 

Phage selection of peptide macrocycles against b-catenin to interfere with Wnt signaling

D. Bertoldo; M. M. G. Khan; P. Dessen; W. Held; J. Huelsken et al. 

Development of potent and selective S. aureus sortase A inhibitors Based on Peptide Macrocycles

I. R. Rebollo; S. Mccallin; D. Bertoldo; J. M. Entenza; P. Moreillon et al. 

Phage selection of chemically stabilized alpha-helical peptide ligands

P. Diderich; D. Bertoldo; P. Dessen; M. M. Khan; I. Pizzitola et al. 

Generation of photoswitchable peptide ligands by phage display

Phage Selection of Photoswitchable Peptide Ligands

S. Bellotto; S. Chen; I. R. Rebollo; H. A. Wegner; C. Heinis 

Improving Bicyclic Peptide Phage Display and Development of Sortase A Inhibitors